-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2023-508800-39-00
5
2020-09-29
Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L85
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2023-503421-19-00
5
2020-08-26
Urothelial cancer
-
2024-512704-20-00
4
2020-06-22
Unresectable and/or metastatic soft-tissue sarcoma after failure of at
-
2024-513005-31-00
5
2020-06-11
Patients with untreated metastatic Estrogen Receptor positive (ER+), H
-
2024-514933-39-00
7
2020-05-26
Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
-
2023-508214-42-00
5
2020-05-25
Previously treated locally advanced and unresectable or metastatic
non
-
2024-513032-14-00
4
2020-04-21
Synovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)
-
2023-506782-56-00
5
2020-03-10
RET-Mutant Medullary Thyroid Cancer
-
2024-515560-30-00
7
2020-03-05
Advanced-stage, relapsed/refractory cancer
-
2023-506783-14-00
5
2020-02-24
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
-
2024-511653-22-00
5
2020-02-12
Cutaneous Squamous Cell Carcinoma (CSCC)
-
2024-518069-89-00
4
2020-02-03
Patients with solid cancers
-
2024-512269-14-00
5
2020-01-27
GIant cell Arteritis
-
2023-509550-55-00
7
2020-01-21
Multiple Myeloma
-
2023-509049-11-00
5
2020-01-01
FIGO stage III ovarian cancer who are eligible for primary cytoreducti
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2023-505088-35-00
9
2019-12-12
Pediatric Solid tumors and primary central nervous system (CNS) tumors
-
2024-512847-21-00
4
2019-12-11
Advanced Synovial Sarcoma
-
2023-508841-42-00
3
2019-10-30
Different types of advanced cancer
-
2024-510776-20-00
5
2019-10-25
Female or male patients with histologically confirmed HR-positive, HER
-
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
-
2024-515616-47-00
5
2019-10-03
Metastatic Renal Cell Carcinoma